Immunohistochemistry (IHC) is a technique that combines anatomical, immunological, and biochemical methods to visualize discrete components in tissues using suitably labelled antibodies that bind to their target antigens in situ. IHC allows researchers to visualize and describe the high-resolution distribution and localization of certain cellular components within cells and their histological background. While IHC methodology has various approaches and permutations, all of the processes are divided into two categories: sample preparation and sample staining. IHC is used for disease diagnosis, biological research, and in drug testing.
The global immunohistochemistry (IHC) market is estimated to be valued at US$ 2,020.2 Million in 2021 and is expected to increase to US$ 3,348.7 Million by 2028, witnessing a CAGR of 7.5% over the forecast period (2021-2028).
Figure 1. Global Immunohistochemistry (IHC) Market Share (%), By Region, 2021
The rising geriatric population is expected to drive the growth of the global immunohistochemistry (IHC) market.
The growing elderly population in both developed (such as UK, Canada, and others) and developing countries (such as India, Brazil, China, and others) will boost the growth of the global immunohistochemistry (IHC) market. The prevalence of age-related disorders is predicted to rise significantly as the global geriatric population grows rapidly. For instance, according to the Organisation for Economic Co-operation and Development (OECD), there were 54 million elderly individuals in the U.S. in 2019. Geriatric populations are likewise significant and expanding in other developed economies around the world. The risk of acquiring diseases increases in direct proportion to a person’s age. As a result, the global prevalence of numerous diseases such as cancer, cardiovascular diseases, and others is predicted to rise as the elderly population grows.
Immunohistochemistry (IHC) Market Report Coverage
||Market Size in 2021:
||US$ 2,020.2 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 3,348.7 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product: Antibodies (Primary Antibodies, Secondary Antibodies), Equipment (Slide Staining Systems, Tissue Microarrays, Tissue Processing Systems, Slide Scanners, Others), Reagents (Histological Stains, Blocking Sera and Reagents, Chromogenic Substrates, Fixation Reagents, Stabilizers, Others), Kits
- By Application: Diagnostics (Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, Others), Drug Testing, Forensic Applications
- By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Others
Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Danaher Corporation, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc., Becton, Dickinson and Company, Takara Bio, Inc., Eagle Biosciences, Inc., Biocare Medical, LLC, Biogenex Laboratories, Diagnostic Biosystems, Inc., and BioVision Inc.
- Increasing prevalence of chronic diseases such as cancers, cardiovascular diseases, and others
- Increasing global geriatric population
- Increasing product launches
|Restraints & Challenges:
- Lack of specificity associated with IHC technology
- High cost of setup
Figure 2. Global Immunohistochemistry (IHC) Market Share (%), By Product, 2021
Global Immunohistochemistry (IHC) Market – Regional Insights
North America is expected to dominate the global immunohistochemistry (IHC) market during the forecast period, owing to a well-developed healthcare infrastructure. Moreover, IHC instruments are increasingly being used in laboratories and diagnostic facilities. The favorable reimbursement structure in this region is further encouraging the market penetration of automated immunohistochemistry devices. The incidence of cancer is also on the rise in this region, which is fueling demand for IHC procedures and resulting in profitable market expansion. For instance, according to National Institutes of Health (NIH) statistics, in 2020, around 1,806,590 new cases of cancer were diagnosed in the United States and 606,520 people died from the disease.
Due to strong economic expansion in nations such as China, India, South Korea, and Singapore, the Asia Pacific region is predicted to grow the fastest. Several factors are contributing to this trend, including increased disposable income, rising healthcare spending, expanding demand for high-quality medical treatment, and rising pharmaceutical and biotech company investments. Other important reasons supporting the growth of the immunohistochemistry (IHC) market in APAC are the rising prevalence of chronic diseases, the fast growing geriatric population, growing academic and government spending in diagnostic research, and the existence of numerous industry participants.
Global Immunohistochemistry (IHC) Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic.
Detection of SARS-CoV-2 using IHC technique, on the other hand, is critical for characterizing disease progression. Thus, impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the global immunohistochemistry (IHC) market over the forecast period. For instance, according to an article published in Laboratory Investigation journal in July 2020, immunohistochemical (IHC) and in situ hybridization (ISH) assays for detection of the SARS-CoV-2 was developed and eight samples from COVID-19 patients were stained. It was found that all eight samples were stained positive by IHC and ISH whereas all specimens from non-COVID-19 patients were IHC and ISH negative.
Global Immunohistochemistry (IHC) Market: Restraint
The lack of specificity associated with IHC technology and the high cost of setup are expected to hamper the global immunohistochemistry (IHC) market. Accurate and early diagnosis of cancer growth is very important in the treatment of any disease. However, IHC technology can be difficult to accept due to its lack of specificity in diagnosing some of the chronic diseases. The high setup costs of IHC devices place a heavy burden on hospitals and diagnostic laboratories in developing countries like China, India and others and limit the growth of the global immunohistochemistry (IHC) market.
Major players operating in the global immunohistochemistry (IHC) market include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Danaher Corporation, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc. , Becton, Dickinson and Company, Takara Bio, Inc., Biosciences, Inc., Biocare Medical, LLC, Biogenex Laboratories, Diagnostic Biosystems, Inc., and BioVision Inc.